World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
17729
World Ranking
3469
National Ranking
299

Mark T. Esser publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark T. Esser sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 160 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark T. Esser D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark T. Esser sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark T. Esser is affiliated with AstraZeneca in the United Kingdom. Their research primarily focuses on the field of Medicine, with a strong emphasis on Infectious Diseases, Epidemiology, and Molecular Biology. Their work spans several subfields including Pulmonary and Respiratory Medicine as well as Molecular Medicine.

The scientist's main research topics include:

  • SARS-CoV-2 and COVID-19 Research
  • Respiratory viral infections research
  • COVID-19 Clinical Research Studies
  • Pneumonia and Respiratory Infections
  • Viral gastroenteritis research and epidemiology
  • Antibiotic Resistance in Bacteria
  • Monoclonal and Polyclonal Antibodies Research

Frequent collaborators include Katie Streicher, Yueh-Ming Loo, Seth Seegobin, Alexey Ruzin, and Kim Rosenthal. These co-authors have contributed significantly to the breadth of studies in which Mark T. Esser has participated.

Mark T. Esser has published extensively in several key venues, including:

  • Open Forum Infectious Diseases
  • Nature Communications
  • Science Translational Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • The Lancet Respiratory Medicine

Some of their recent papers are:

  • Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants, 2020, New England Journal of Medicine
  • Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail, 2021, Nature Microbiology
  • Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial, 2022, The Lancet Respiratory Medicine
  • The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans, 2022, Science Translational Medicine
  • SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity, 2021, Cell Reports

Best Publications

  • Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

    Luisa L. Villa;Gonzalo Perez;Susanne K. Kjaer;Jorma Paavonen

  • Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

    Suzanne M. Garland;Suzanne M. Garland;Mauricio Hernandez-Avila;Cosette M. Wheeler;Gonzalo Perez

  • Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

    Luisa L. Villa;Ronaldo L.R. Costa;Carlos A. Petta;Rosires P. Andrade

  • Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

    Elmar A Joura;Sepp Leodolter;Mauricio Hernandez-Avila;Cosette M Wheeler

  • High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

    L. L. Villa;R. L. R. Costa;C. A. Petta;R. P. Andrade

  • Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.

    M. Pamela Griffin;Yuan Yuan;Therese Takas;Joseph B. Domachowske

  • Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

    Luisa L. Villa;Kevin A. Ault;Anna R. Giuliano;Ronaldo L.R. Costa

  • Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

    Nubia Muñoz;Ricardo Manalastas;Punee Pitisuttithum;Damrong Tresukosol

  • Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

    JL Rossio;MT Esser;K Suryanarayana;DK Schneider

  • Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

    Sven-Eric Olsson;Luisa L. Villa;Ronaldo L.R. Costa;Carlos A. Petta

  • Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

    Keith S. Reisinger;Stan L. Block;Eduardo Lazcano-Ponce;Rudiwilai Samakoses

  • Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay

    David Opalka;Charles E. Lachman;Stefani A. MacMullen;Kathrin U. Jansen

  • The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

    Unknown

  • Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

    Unknown

  • Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

    Dennis Dias;Jeff Van Doren;Sonela Schlottmann;Sheri Kelly

  • Memory T cells and vaccines.

    Mark T. Esser;Rocio D. Marchese;Lisa S. Kierstead;Lynda G. Tussey

  • Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.

    Jinhui Dong;Seth J Zost;Allison J Greaney;Allison J Greaney;Tyler N Starr

  • Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

    Luisa L. Villa;Gonzalo Perez;Susanne Krüger Kjær;Jorma Paavonen

  • Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

    Unknown

  • Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

    Myron J Levin;Anna-Barbara Moscicki;Lin-Ye Song;Terrence Fenton

  • Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.

    Joseph B. Domachowske;Anis A. Khan;Mark T. Esser;Kathryn Jensen

  • Differential Incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and Major Histocompatibility Complex Class I and II Molecules into Human Immunodeficiency Virus Type 1 Virions and Microvesicles: Implications for Viral Pathogenesis and Immune Regulation

    Mark T. Esser;David R. Graham;Lori V. Coren;Charles M. Trubey

  • Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120

    Mark T. Esser;Toshiyuki Mori;Isabelle Mondor;Quentin J. Sattentau

  • An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions

    Joseph G. Joyce;Isaac J. Krauss;Hong C. Song;David W. Opalka

Frequent Co-Authors

Luisa L. Villa
Luisa L. Villa Universidade de São Paulo
Judith Falloon
Judith Falloon Horizon Therapeutics (United States)
Laura A. Koutsky
Laura A. Koutsky University of Washington
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Jorma Paavonen
Jorma Paavonen University of Helsinki
Cosette M. Wheeler
Cosette M. Wheeler University of New Mexico
Jesse D. Bloom
Jesse D. Bloom Fred Hutchinson Cancer Research Center
Alfred J. Saah
Alfred J. Saah MSD (United States)
Ligia A. Pinto
Ligia A. Pinto Leidos (United States)
Allan Hildesheim
Allan Hildesheim National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various related healthcare careers, many of which offer flexible online education options. For those interested in nursing with a focus on immunological care, exploring an accelerated FNP program can be a fast track to becoming a Family Nurse Practitioner. This specialization often serves as a foundation to advance into more acute care settings.

Transitioning from an FNP role to acute care requires additional certification, and understanding the pathway to fnp to acute care certification is crucial for career growth. This shift allows practitioners to handle more complex immunology-related cases often seen in hospital environments.

For those starting without a nursing background, enrolling in online ADN programs for non nurses provides an accessible entry point into nursing. These programs prepare students for nursing licenses and set the stage for advanced studies in immunology or related nursing fields.

Financial considerations are also important. Understanding how much does a dnp make can help you gauge the return on investment for pursuing a Doctor of Nursing Practice degree, especially if you aim to take on leadership roles within immunology-focused healthcare settings.

Best Scientists Citing Mark T. Esser

Trending Scientists

Recently Published Articles